Mutant fragments of OspA and methods and uses relating thereto
US11572392B2 · kind B2 · utility
3Cited by
8References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2020 |
| Grant date | Feb 7, 2023 |
| Priority date | — |
| Expiry date | Aug 11, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.